Cargando…
Molecular analysis of iduronate -2- sulfatase gene in Tunisian patients with mucopolysaccharidosis type II
Mucopolysaccharidosis type II (MPS II, Hunter syndrome) is X-linked recessive lysosomal storage disorder resulting from the defective activity of the enzyme iduronate-2-sulfatase (IDS). Hunter disease can vary from mild to severe, depending on the level of enzyme deficiency. We report the IDS mutati...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3115838/ https://www.ncbi.nlm.nih.gov/pubmed/21605424 http://dx.doi.org/10.1186/1746-1596-6-42 |
_version_ | 1782206176420691968 |
---|---|
author | Chkioua, Latifa Khedhiri, Souhir Ferchichi, Salima Tcheng, Rémy Chahed, Henda Froissart, Roseline Vianey-Saban, Christine Laradi, Sandrine Miled, Abdelhedi |
author_facet | Chkioua, Latifa Khedhiri, Souhir Ferchichi, Salima Tcheng, Rémy Chahed, Henda Froissart, Roseline Vianey-Saban, Christine Laradi, Sandrine Miled, Abdelhedi |
author_sort | Chkioua, Latifa |
collection | PubMed |
description | Mucopolysaccharidosis type II (MPS II, Hunter syndrome) is X-linked recessive lysosomal storage disorder resulting from the defective activity of the enzyme iduronate-2-sulfatase (IDS). Hunter disease can vary from mild to severe, depending on the level of enzyme deficiency. We report the IDS mutation and polymorphisms causing the Hunter syndrome in patients from one family in Tunisia PATIENTS AND METHODS: A preliminary diagnosis was made by qualitative detection of urinary glycosaminoglycans of the suspected MPS II probands. The IDS mutation and polymorphisms were determined on these probands and their family members by amplifying and sequencing each of the exons and intron-exon junctions of IDS gene. RESULTS: The studied probands were homoallelic for p.R88P mutation. In addition, three known polymorphisms/sequence variants: IVS3-16 (c.419-16 delT), T214M (c.641C > T), T146T (c.438 C > T), IVS5-87(c.709-87G > A) and one previously unknown: IVS7+38(c.1006+38T > C were identified in the MPS II patients. These are the first Tunisian MPS II patients to be genotyped. CONCLUSION: The identification of these mutation and polymorphisms and their genotype-phenotype correlation should facilitate prenatal diagnosis and counseling for MPS II in Tunisia, where a very high rate of consanguinity exists. |
format | Online Article Text |
id | pubmed-3115838 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-31158382011-06-16 Molecular analysis of iduronate -2- sulfatase gene in Tunisian patients with mucopolysaccharidosis type II Chkioua, Latifa Khedhiri, Souhir Ferchichi, Salima Tcheng, Rémy Chahed, Henda Froissart, Roseline Vianey-Saban, Christine Laradi, Sandrine Miled, Abdelhedi Diagn Pathol Case Report Mucopolysaccharidosis type II (MPS II, Hunter syndrome) is X-linked recessive lysosomal storage disorder resulting from the defective activity of the enzyme iduronate-2-sulfatase (IDS). Hunter disease can vary from mild to severe, depending on the level of enzyme deficiency. We report the IDS mutation and polymorphisms causing the Hunter syndrome in patients from one family in Tunisia PATIENTS AND METHODS: A preliminary diagnosis was made by qualitative detection of urinary glycosaminoglycans of the suspected MPS II probands. The IDS mutation and polymorphisms were determined on these probands and their family members by amplifying and sequencing each of the exons and intron-exon junctions of IDS gene. RESULTS: The studied probands were homoallelic for p.R88P mutation. In addition, three known polymorphisms/sequence variants: IVS3-16 (c.419-16 delT), T214M (c.641C > T), T146T (c.438 C > T), IVS5-87(c.709-87G > A) and one previously unknown: IVS7+38(c.1006+38T > C were identified in the MPS II patients. These are the first Tunisian MPS II patients to be genotyped. CONCLUSION: The identification of these mutation and polymorphisms and their genotype-phenotype correlation should facilitate prenatal diagnosis and counseling for MPS II in Tunisia, where a very high rate of consanguinity exists. BioMed Central 2011-05-23 /pmc/articles/PMC3115838/ /pubmed/21605424 http://dx.doi.org/10.1186/1746-1596-6-42 Text en Copyright ©2011 Chkioua et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Case Report Chkioua, Latifa Khedhiri, Souhir Ferchichi, Salima Tcheng, Rémy Chahed, Henda Froissart, Roseline Vianey-Saban, Christine Laradi, Sandrine Miled, Abdelhedi Molecular analysis of iduronate -2- sulfatase gene in Tunisian patients with mucopolysaccharidosis type II |
title | Molecular analysis of iduronate -2- sulfatase gene in Tunisian patients with mucopolysaccharidosis type II |
title_full | Molecular analysis of iduronate -2- sulfatase gene in Tunisian patients with mucopolysaccharidosis type II |
title_fullStr | Molecular analysis of iduronate -2- sulfatase gene in Tunisian patients with mucopolysaccharidosis type II |
title_full_unstemmed | Molecular analysis of iduronate -2- sulfatase gene in Tunisian patients with mucopolysaccharidosis type II |
title_short | Molecular analysis of iduronate -2- sulfatase gene in Tunisian patients with mucopolysaccharidosis type II |
title_sort | molecular analysis of iduronate -2- sulfatase gene in tunisian patients with mucopolysaccharidosis type ii |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3115838/ https://www.ncbi.nlm.nih.gov/pubmed/21605424 http://dx.doi.org/10.1186/1746-1596-6-42 |
work_keys_str_mv | AT chkioualatifa molecularanalysisofiduronate2sulfatasegeneintunisianpatientswithmucopolysaccharidosistypeii AT khedhirisouhir molecularanalysisofiduronate2sulfatasegeneintunisianpatientswithmucopolysaccharidosistypeii AT ferchichisalima molecularanalysisofiduronate2sulfatasegeneintunisianpatientswithmucopolysaccharidosistypeii AT tchengremy molecularanalysisofiduronate2sulfatasegeneintunisianpatientswithmucopolysaccharidosistypeii AT chahedhenda molecularanalysisofiduronate2sulfatasegeneintunisianpatientswithmucopolysaccharidosistypeii AT froissartroseline molecularanalysisofiduronate2sulfatasegeneintunisianpatientswithmucopolysaccharidosistypeii AT vianeysabanchristine molecularanalysisofiduronate2sulfatasegeneintunisianpatientswithmucopolysaccharidosistypeii AT laradisandrine molecularanalysisofiduronate2sulfatasegeneintunisianpatientswithmucopolysaccharidosistypeii AT miledabdelhedi molecularanalysisofiduronate2sulfatasegeneintunisianpatientswithmucopolysaccharidosistypeii |